Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Jun 8, 2006

Premium

Title: Therapeutic RNAi Agents for Treating Psoriasis

Number: 20060115455

Filed: Oct. 21, 2005

Lead Inventor: Ken Reed, Benitec

According to the patent application's abstract, the invention "provides compositions and methods suitable for delivering RNAi agents against genetic targets in skin tissues so as to treat psoriasis."


Title: Therapeutic RNAi Agents for Treating Restenosis

Number: 20060115454

Filed: Oct. 14, 2005

Lead Inventor: Linda Couto, Benitec

According to the patent application's abstract, the invention "provides compositions and methods suitable for delivering RNAi agents against genetic targets in vascular and adjacent tissue in vivo so as to treat restenosis."


Title: Apparatus and System Having Dry Gene-Silencing Compositions

Number: 20060115461

Filed: Nov. 18, 2005

Lead Inventor: Barbara Robertson, Dharmacon

The patent application, its abstract states, covers "a reverse-transfection apparatus … for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene-silencing composition that has at least a first siRNA which silences a first target gene. The gene-silencing composition can be configured such that the at least first siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the at least first siRNA can include a modification or a conjugate. The reverse-transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.